title: Hepatitis B vaccination and the rate of seroconversion in high risk contacts.
abstract: Twenty-seven employees of a blood transfusion centre, Calcutta were vaccinated with hepatitis B vaccine (recombinant DNA technology), 20 micrograms/1 ml intramuscularly on 0, 8, 32 weeks interval. The seroconversion rate at 8, 32, 40 weeks were 29.6%, 55.5% and 100% respectively. The recombinant hepatitis B vaccine is acceptable and safe. The seroconversion rate is comparable to plasma derived hepatitis B vaccine.
authors.affiliation: B R Singh Hospital, Calcutta.
authors.forename: B
authors.initials: B
authors.lastname: Sengupta
authors.forename: A
authors.initials: A
authors.lastname: Sarkar
authors.forename: M
authors.initials: M
authors.lastname: De
authors.forename: P
authors.initials: P
authors.lastname: Lahiri
authors.forename: D K
authors.initials: DK
authors.lastname: Bhattacharya
mesh_terms: D001771:Blood Banks; D001782:Blood Donors; D005260:Female; D006282:Health Personnel; D006509:Hepatitis B / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood; D006512:Hepatitis B Core Antigens / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood; D017325:Hepatitis B Vaccines / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008403:Mass Screening; D009784:Occupational Diseases / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control*; D012307:Risk Factors; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000008:administration & dosage*
chemical_list: D006510:Hepatitis B Antibodies; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; C075655:Recombivax HB; D014614:Vaccines, Synthetic